Genes Associated with Neuraminidase-Deficiency Disorders (Sialidase/Gene Mapping/Complementation Analysis) 0

Total Page:16

File Type:pdf, Size:1020Kb

Genes Associated with Neuraminidase-Deficiency Disorders (Sialidase/Gene Mapping/Complementation Analysis) 0 Proc. Natl. Acad. Sci. USA Vol. 83, pp. 1817-1821, March 1986 Genetics Sialidosis and galactosialidosis: Chromosomal assignment of two genes associated with neuraminidase-deficiency disorders (sialidase/gene mapping/complementation analysis) 0. THOMAS MUELLER, W. MICHAEL HENRY, LINDA L. HALEY, MARY G. BYERS, ROGER L. EDDY, AND THOMAS B. SHOWS Department of Human Genetics, Roswell Park Memorial Institute, New York State Department of Health, Buffalo, NY 14263 Communicated by Victor A. McKusick, November 14, 1985 ABSTRACT The inherited human disorders sialidosis and galactosialidosis heterozygotes have not consistently shown galactosialidosis are the result of deficiencies of glycoprotein- a reduction in either ,B-galactosidase or a-neuraminidase (2, specific a-neuraminidase (acylneuraminyl hydrolase, EC 9, 13-16). Complementation studies from a number of labo- 3.2.1.18; sialidase) activity. Two genes were determined to be ratories show that the primary defect is different from that necessary for expression of neuraminidase by using human- causing single deficiencies of P-galactosidase (GM1- mouse somatic cell hybrids segregating human chromosomes. gangliosidosis) or neuraminidase (7, 17-19). The residual A panel of mouse RAG-human hybrid cells demonstrated a 3-galactosidase activity in galactosialidosis fibroblasts exists single-gene requirement for human neuraminidase and allowed entirely as a monomer with an absence of a large multimer assignment of this gene to the (pter-_q23) region of chromo- form found in normal cells (20). The mutation causing some 10. A second panel of mouse thymidine kinase (TK)- galactosialidosis also causes a decrease in turnover time due deficient LM/TK-human hybrid cells demonstrated that to an increased susceptibility of,-galactosidase to proteo- human neuraminidase activity required both chromosomes 10 lytic degradation (20, 21). The P-galactosidase deficiency, but and 20 to be present. Analysis of human neuraminidase not the neuraminidase deficiency, can be corrected by the expression in interspecific hybrid cells or polykaryocytes addition of protease inhibitors (21-24). This could be accom- formed from fusion of mouse RAG (hypoxanthine/guanine plished also with the addition of a "corrective factor" phosphoribosyltransferase deficient) or LM/TK- cell lines concentrated from cell culture medium, which has charac- with human sialidosis or galactosialidosis fibroblasts indicated teristics of a glycoprotein (23-25). Recent evidence suggests that the RAG cell line complemented the galactosialidosis that the mutation causing galactosialidosis results in an defect, but the LM/TK- cell line did not. This eliminates the absence of a 32-kDa glycoprotein in anti-p-galactosidase requirement for this gene in RAG-human hybrid cells and immunoprecipitates, and this protein was postulated to be the explains the different chromosome requirements of these two primary defect in galactosialidosis (23). hybrid panels. Fusion of LM/TK- cell hybrids lacking chro- We present evidence for the chromosomal assignment of mosome 10 or 20 (phenotype 10+,20- and 10-,20+) and two genes required for the expression of human neuramini- neuraminidase-deficient fibroblasts confirmed by complemen- dase in somatic cell hybrids. In addition, our evidence tation analysis that the sialidosis disorder results from a indicates that the sialidosis and galactosialidosis diseases are mutation on chromosome 10, presumably encoding the caused by mutations in these genes located on chromosomes neuraminidase structural gene. Galactosialidosis is caused by a 10 and 20, respectively. A portion of this work has been mutation in a second gene required for neuraminidase expres- presented in abstract form (26). sion located on chromosome 20. MATERIALS AND METHODS Several inherited diseases have been found to be associated with a deficiency of glycoprotein-specific N-acetyl-a- Fibroblasts and Hybrid Cells. The fibroblasts used were neuraminidase activity (acylneuraminyl hydrolase, EC GM1718, derived from an infantile-onset variant of sialidosis 3.2.1.18; sialidase). These disorders are typically classified as type II (mucolipidosis I), and GM806, derived from a subject the sialidoses, which have only a neuraminidase deficiency, with an early-onset form of galactosialidosis. Hybrid cells and the galactosialidoses, which have a coexistent deficiency were made by fusing normal human cells or cells with of P-galactosidase (1, 2). The sialidosis disorder, originally balanced chromosomal translocations with either mouse termed lipomucopolysaccharidosis (3), includes several var- LM/TK- [thymidine kinase (TK) deficient] or mouse RAG iants with different degrees of clinical severity, including an (hypoxanthine/guanine phosphoribosyl transferase defi- adult-onset form known as sialidosis type I and the infantile- cient) cells and selecting clones in hypoxanthine/aminopter- onset variant known as mucolipidosis I or sialidosis type II (4, in/thymidine selection medium as described (27). The pres- 5). The galactosialidosis disorder, which has also been ence of human chromosomes was determined in each hybrid termed the Goldberg Syndrome (6), GM1 gangliosidosis type clone by scoring for previously mapped human enzyme 4 (7), the cherry-red-spot-myoclonus syndrome with demen- markers and by karyotype analysis with trypsin/Giemsa tia (2), and the juvenile-onset form of sialidosis type II (8), is banding (28). also clinically heterogeneous (9, 10). Neuraminidase Assays. Hybrids used for chromosomal The primary defect in the sialidoses is thought to be a localization studies were analyzed for human neuraminidase mutation in the neuraminidase structural gene. Obligate expression as freshly harvested cultures due to the lability of heterozygotes show a gene-dosage effect and have approxi- this enzyme to freezing. Hybrid harvests were scored for mately halfthe normal neuraminidase levels (11, 12). Obligate neuraminidase and analyzed karyotypically on the same passage. Hybrid cultures were rinsed in Dulbecco's phos- The publication costs of this article were defrayed in part by page charge phate-buffered saline and scraped from flasks with a rubber payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Abbreviation: TK, thymidine kinase. 1817 Downloaded by guest on September 30, 2021 1818 Genetics: Mueller et al. Proc. Natl. Acad. Sci. USA 83 (1986) policeman. Cell pellets were homogenized gently in cold Table 2. Human-mouse hybrid cell neuraminidase activity distilled water by using a Dounce type homogenizer with a Teflon pestle. Neuraminidase activity was determined by a RAG Neuraminidase LM/TK- Neuraminidase procedure modified from that of Warner and O'Brien (29). hybrids Activity Score hybrids Activity Score Homogenates (20 ,ul) were incubated with 5 .ul of 1 M sodium ATR-22 6.0 - ICL-6 10.8 + acetate (pH 4.2) and 5 ALI of 7.1 mM 4-methylumbelliferyl-a- DUA-1 CH 2.0 - NSL-16 5.1 - neuraminide (Koch-Light Laboratories, Colnbrook, U.K.) at DUA-5 BA 4.0 - TSL-2 10.3 + 370C for 30 min. Reactions were terminated by adding 2 ml of DUM-13 29.8 + TSL-2 CF 3.7 - 0.85 M glycine (pH 10), and the fluorescence was determined DUM-23 36.3 + TSL-6F 6.0 - with an Aminco fluorimeter. The inclusion of bovine serum JSR-2 6.7 - VTL-6 10.3 + albumin at 1 mg/ml or 1 mM CaCl2 in assays or the JSR-6C 24.5 + VTL-11 4.1 - preparation of homogenates in the presence of 1 mM JSR-6D 21.2 + VTL-13 4.4 - phenylmethylsulfonyl fluoride had no effect on activity. JWR-22H 57.3 + VTL-14 4.5 - Protein concentration was measured by using a modification JWR-26C 25.3 + VTL-15 5.8 - of the Folin phenol procedure (30). RAS-M3 26.0 + VTL-16 10.6 + Complementation Analysis. Each of the two cultures used REW-4 8.0 - VTL-17 4.3 - in complementation experiments was seeded at half the REW-8I C4 5.0 - VTL-18 4.4 - confluent cell density, and the mixture was cultivated over- REW-11 5.5 - VTL-19 3.2 - night. These cultures were fused by using 42% (wt/vol) REX-11 BF 20.5 + VTL-21 4.2 - polyethylene glycol 1000 (Koch-Light Laboratories) contain- REW-13 57.0 + VTL-22 5.0 - ing 7% (vol/vol) dimethyl sulfoxide (31), and the resulting REW-15 34.8 + VTL-23 3.4 - polykaryocytes were enriched by sedimentation velocity REX-26 6.3 - WIL-2 3.5 - under sterile conditions with a Sta-Put apparatus (Johns REX-33 5.0 - WIL-2 C 3.9 - Scientific, Toronto) as described (19). This polykaryocyte REX-57 BB 5.0 - WIL-6 10.4 + fraction was cultured for 10-14 days, and the neuraminidase SIR-1 4.0 - WIL-8 12.9 + activity was determined along with cultures of each parental XER-8 21.3 + WIL-8S 9.6 + cell type and a cocultivated mixture. In complemnentation XER-11 27.6 + WIL-8Y 11.9 + experiments involving human fibroblasts and RAG or XER-15 21.3 + WIL-li 14.5 + LM/TK- cells, the polykaryocytes were cultivated in XTR-1 27.0 + WIL-13 4.0 - hypoxanthine/aminopterin/thymidine selection medium in XTR-1 BD 35.7 + WIL-14 5.7 - order to inhibit growth of the unfused mouse parental cells. XTR-3 BH 20.8 + WIL-14 C 6.1 - A significant increase in the neuraminidase activity of the XTR-22 26.3 + polykaryocyte fraction over that of the cocultivated mixture The neuraminidase activity of hybrid cells is the mean of at least and parental cell activity range, as determined with Student's three separate harvests and is expressed in nmol/hr per mg of t test (at the 1% confidence level), was assumed to indicate homogenate protein. Neuraminidase scores are based on statistically complementation. significant increases over the activity of parental mouse cells (Table 1). Hybrid clone XTR-3 BH contains del(10)(q23--qter) (deletion in RESULTS chromosome 10 in region q23--qter). Somatic Cell Hybrid Mapping of Neuraminidase. The pres- ence of human neuraminidase activity in human-mouse mg for LM/TK- hybrids) were scored negative for human somatic cell hybrids that segregate human chromosomes activity.
Recommended publications
  • Neuroradiologic Findings in Fucosidosis, a Rare Lysosomal Storage Disease
    Neuroradiologic Findings in Fucosidosis, a Rare Lysosomal Storage Disease James M. Provenzale, Daniel P. Barboriak, and Katherine Sims Summary: Fucosidosis is a rare lysosomal storage disorder with vacuolated secondary lysosomes containing some fine the clinical features of mental retardation, cardiomegaly, dysos- fibrillar material and lamellated membrane structures. tosis multiplex, progressive neurologic deterioration, and early A magnetic resonance (MR) examination at the age of death. The neuroradiologic findings in two patients are reported, 10 years showed confluent regions of hyperintense signal and include abnormalities within the globus pallidus (both pa- on T2-weighted images in the periventricular regions, tients) and periventricular white matter (one patient). most prominent surrounding the atria of the lateral ventri- cles. Hyperintense signal was noted in the globus pallidus Index terms: Brain, metabolism; Degenerative disease, Pediatric on T1-weighted images, with corresponding hypointense neuroradiology signal on T2-weighted images (Fig 1). Fucosidosis is a rare metabolic disorder caused by decreased amounts of the enzyme Case 2 a-L-fucosidase, which results in the accumula- A 2-year-old boy was examined for speech delay and tion of fucose-rich storage products within psychomotor retardation. He was born at term after a many organs, including the brain. Patients with normal pregnancy, and appropriate development oc- this disorder usually have delayed intellectual curred during the first year of life. However, by age 2 years, and motor development, and often die within the patient had not developed speech, exhibited autistic the first decade of life. Computed tomographic behavior, and performed motor tasks poorly. Physical ex- (CT) findings have been reported in a few cases amination findings included coarsened facial features, nar- (1, 2).
    [Show full text]
  • Program Download
    5TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE ROME, ITALY NOVEMBER 1-4 2017 EMBRACING INNOVATION ADVANCING THE CURE ISMRD would like to say a very special thank you to the following organizations and companies who have very generously given donations to support the 5th International Conference on Glycoproteinoses. THE WAGNER FOUNDATION ISMRD is very grateful for all the help and support that Symposia has given us in the organization of our Conference on-the-ground support in Rome. Dedicated to helping patients in the rare disease community with unmet medical needs Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company committed to creating new therapeutics to combat serious, debilitating diseases. www.ultragenyx.com © 2017 Ultragenyx Pharmaceutical Inc. www.ultragenyx.com 8/16 MRCP-UGNX-00008 5TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE 2017 Welcome to Rome! On behalf of ISMRD, I would like to welcome Of course, our conference would not take you all to the Fifth Glycoproteinoses place without significant charitable donations. International Conference on 'Embracing I would like to thank the following companies Innovation and Advancing the Cure'. and foundations, Ultragenyx, EveryLife Foundation, Sanofi/Genzyme, Amicus and The ISMRD is thrilled to bring our International Wagner Foundation. I would also like to extend Conference to Europe allowing us to connect our very grateful thanks to Symposia who are with families, researchers, clinicians, support event planners, who have worked alongside us groups and others who work in the field of rare here in Rome and have helped you check in at diseases. But, more importantly to help make registration. They will be on site throughout the the invaluable connections for families who meeting offering support and answering any perhaps have never met another family with questions you may have.
    [Show full text]
  • Fast Urinary Screening of Oligosaccharidoses by MALDI-TOF/TOF Mass Spectrometry
    Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry. Laurent Bonesso, Monique Piraud, Céline Caruba, Emmanuel van Obberghen, Raymond Mengual, Charlotte Hinault To cite this version: Laurent Bonesso, Monique Piraud, Céline Caruba, Emmanuel van Obberghen, Raymond Mengual, et al.. Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry.. Orphanet Journal of Rare Diseases, BioMed Central, 2014, 9 (1), pp.19. 10.1186/1750-1172-9-19. inserm- 00945684 HAL Id: inserm-00945684 https://www.hal.inserm.fr/inserm-00945684 Submitted on 12 Feb 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Bonesso et al. Orphanet Journal of Rare Diseases 2014, 9:19 http://www.ojrd.com/content/9/1/19 RESEARCH Open Access Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry Laurent Bonesso1, Monique Piraud5, Céline Caruba1, Emmanuel Van Obberghen1,2,3,4, Raymond Mengual1† and Charlotte Hinault1,2,3,4*† Abstract Background: Oligosaccharidoses, which belong to the lysosomal storage diseases, are inherited metabolic disorders due to the absence or the loss of function of one of the enzymes involved in the catabolic pathway of glycoproteins and indirectly of glycosphingolipids.
    [Show full text]
  • Fucosidosis: Ultrastructural Study of Conjunctiva and Skin and Enzyme Analysis of Tears
    Fucosidosis: ultrastructural study of conjunctiva and skin and enzyme analysis of tears /. Libert,9 F. Van Hoof," and M. Tondeur*** Conjunctival and skin biopsies from two new patients with fucosidosis were studied by electron microscopy. In both tissues, the connective tissue cells and the capillary endothelial cells were filled with single membrane limited inclusions of two types: (1) Clear inclusions containing a fibrillogranular reticulum. (2) Dark inclusions with a dense granular material. Specific stainings in ultrastructure suggest that these inclusions contain oligosaccharide chains. The ultrastructural aspect is characteristic for fucosidosis. Enzyme studies on tears realize an easy and secure technique for the diagnosis of the disease. -Lhe interest of conjunctival biopsy in the io-i5 Most of the lysosomal acid hydrolases study of storage diseases is now abun- can be assayed in tears, and their defi- dantly documented. Pathologic changes ciency allows the diagnosis of several other have been demonstrated in the systemic inborn lysosomal diseases.16"18 mucopolysaccharidoses,1 several mucolip- Fucosidosis, an autosomal lysosomal dis- idoses,2"5 Fabry's disease,6'7 Niemann- ease, is characterized by the absence or the Pick's disease,8 and cystinosis.9 profound deficiency of a-L-fucosidase,19"21 The usefulness of tears for the enzymatic which results in the widespread accumula- screening of inborn lysosomal diseases was tion of fucose-containing glycosphingolip- recognized about two years ago and ap- ids, oligosaccharides, and polysaccharides, plied to Tay-Sachs and Fabry's diseases.7' together with an increased excretion of fucosides in urine.22 Clinically, a severe and a mild phenotype have been distin- From the Departments of Ophthalmology" and guished.23' 24 The patients suffering from Pediatrics,00" Hopital Saint-Pierre, Universite Libre de Bruxelles, and from the International the severe form present a progressive psy- Institute of Cellular and Molecular Patholo- chomotor retardation and a moderate gy,00 Universite Catholique de Louvain.
    [Show full text]
  • 4Th Glycoproteinoses International Conference Advances in Pathogenesis and Therapy
    Program & Abstracts 4TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE ADVANCES IN PATHOGENESIS AND THERAPY ISMRD ST. LOUIS, MISSOURI, UNITED STATES Program & Abstracts I SM R D ADVANCES IN PATHOGENESIS AND THERAPY Program & Abstracts ISMRD would like to say A Very Special Thank You to the following organizations and companies who have very generously given donations and sponsorship to support the 4th International Conference on Glycoproteinoses THE PRENILLE EDWARD MALLINCKRODT FOUNDATION JR FOUNDATION MARK HASKINS I SM R D 4TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE 2015 ADVANCES IN PATHOGENESIS AND THERAPY Program & Abstracts ISMRD is very proud to display 10 featured Expression of Hope artworks to be Auctioned at the Gala Dinner. These beautiful prints are from Genzyme’s featured Artwork selection. Contents Welcome 1 SCIENTIFIC COMMITTEE: Stuart Kornfeld ISMRD Mission & Governance 3 (Chair, Scientifi c Planning Committee) Steve Walkley Sara Cathey ISMRD General Information 5 Richard Steet Sean Thomas Ackley, Philippines Miriam Storchli, Switzerland Alessandra d’Azzo ‘Hope’ by Sarah Noble, New Zealand Scientifi c Program 9 FAMILY CONFERENCE COMMITTEE: Family Program for Mucolipidosis 11 Jenny Noble (Conference Organiser) Jackie James (Conference Organiser Family Program For Alpha Mannosidosis /Sialidosis/ 13 - St. Louis) Fucosidosis/Aspartylglucosaminuria Mark Stark John Forman ‘All around the world’ by Zih Yun Li , Taiwan Childrens Program 16 Susan Kester Carolyn Paisley-Dew Tish Adkins Abstracts 17 Sara DeAngelis, Russia Gayle Rose, United States Speaker Profi les 60 Delegates 81 Helen Walker, Australia Nicklas Harkins, Canada Naomi Arai, Japan David Wentworth, Serbia I SM R D 4TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE 2015 ADVANCES IN PATHOGENESIS AND THERAPY Program & Abstracts On behalf of the Scientifi c Planning Committee, I want to extend a warm welcome to all the investigators and Welcome! families who have traveled to St.
    [Show full text]
  • Mucopolysaccharidoses and Mucolipidoses
    J Clin Pathol: first published as 10.1136/jcp.s3-8.1.64 on 1 January 1974. Downloaded from J. clin. Path., 27, Suppl. (Roy. Coll. Path.), 8, 64-93 Mucopolysaccharidoses and mucolipidoses F. VAN HOOF From the Laboratoire de Chimie Physiologique, Universite Catholique de Louvain, and International Institute of Cellular and Molecular Pathology, Brussels, Belgium Many different syndromes are classified as muco- THE CHEMICAL ERA polysaccharidoses, and, despite remarkable progress Chemical studies, performed mainly by groups in the biochemical understanding of these diseases, working with A. Dorfman, in Chicago and K. much remains to be learned and many cases still Meyer, in New York, have provided most of the escape classification. new knowledge in the field by analysis of tissue and Mucopolysaccharidoses are inborn storage dis- urinary mucopolysaccharides in patients (Dorfman eases, characterized by a complex accumulation of and Lorincz, 1957; Meyer, Grumbach, Linker, and mucopolysaccharides and of glycolipids within the Hoffman, 1958; Meyer, Hoffman, Linker, lysosomes. Sixteen human diseases correspond to Grumbach, and Sampson, 1959). These provided the this definition, of which nine have been presently basis for the subdivision of the 'Hurler syndrome' explained by the deficiency of an acid hydrolase. into six subgroups (McKusick, Kaplan, Wise, They are somewhat arbitrarily divided into muco- Hanley, Suddarth, Sevick, and Maumanee, 1965). polysaccharidoses and mucolipidoses. In muco- The possibility that mucopolysaccharidoses could polysaccharidoses, mucopolysaccharides are the result from an excessive biosynthesis of muco- main storage substances, although an abnormal polysaccharides was suggested by Matalon and accumulation of complex lipids is practically always Dorfman (1966). copyright. disclosed at least by the ultiastructural examination.
    [Show full text]
  • International Conference
    5TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE Rome, Italy November 1-4 2017 EMBRACING INNOVATION ADVANCING THE CURE PROGRAM & ABSTRACTS 5TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE ROME, ITALY NOVEMBER 1-4 2017 EMBRACING INNOVATION ADVANCING THE CURE ISMRD would like to say a very special thank you to the following organizations and companies who have very generously given donations to support the 5th International Conference on Glycoproteinoses. ISMRD is an internationally focused not-for-profi t organization whose mission is to advocate for families and patients aff ected by one of the following disorders. Alpha-Mannosidosis THE WAGNER FOUNDATION Aspartylglucosaminuria Beta-Mannosidosis Fucosidosis Galactosialidosis ISMRD is very grateful for all the help and support that Symposia has given us Sialidosis (Mucolipidosis I) in the organization of our Conference on-the-ground support in Rome. Mucolipidosis II, II/III, III alpha/beta Mucolipidosis III Gamma Schindler Disease EMBRACING INNOVATION ADVANCING THE CURE SCIENTIFIC COMMITTEE: Alessandra d’Azzo CHAIR Contents Amelia Morrone Italy Richard Steet USA Welcome 2 Heather Flanagan-Steet USA ISMRD Mission & Governance 4 Dag Malm Norway ISMRD General Information 6 Thomas Braulke Dedicated to helping patients Germany in the rare disease community Stuart Kornfeld with unmet medical needs Scientifi c Program 10 USA Ultragenyx Pharmaceutical Inc. is a clinical-stage Family Program 14 ISMRD CONFERENCE biopharmaceutical company committed to creating new COMMITTEE: therapeutics to combat serious,
    [Show full text]
  • Mucolipidosis Type I)
    endothelial keratoplasty in 200 eyes: early chal- A lenges and techniques to enhance donor adherence. J Cataract Refract Surg. 2006;32(3): 411-418. 4. Culbertson WW. Descemet stripping endothe- lial keratoplasy. Int Ophthalmol Clin. 2006;46 (3):155-168. 5. Ellis DR, Cohen KL. Sulfur hexafluoride gas in the repair of Descemet’s membrane detachment. Cornea. 1995;14(4):436-437. 6. Sorenson A. DSEK prolene pull. http://www .newmediamedicine.com/videos/2007/01/17 /dsek-prolene-pull-andrew-sorenson-md/. Ac- cessed March 18, 2007. Cherry Red Spot in Sialidosis (Mucolipidosis Type I) The differential diagnosis of a cherry red spot in the macula includes cen- tral retinal artery occlusion and metabolic storage diseases such as B Tay-Sachs disease, Sandhoff dis- ease, Niemann-Pick disease, Fabry disease, Gaucher disease, and siali- dosis. We report a case of an ado- lescent who, at a routine ophthal- mic examination, was found to have a cherry red spot in the maculae of both eyes. Laboratory investigation results showed that the patient had mucolipidosis type I, which is a rare lysosomal storage disease with clini- cal and histologic findings similar to C the mucopolysaccharidoses and the sphingolipidoses. Report of a Case. A 14-year-old white boy complained of difficulty seeing the blackboard at school. A screen- ing eye examination found de- creased distance vision in both eyes. He was of normal intelligence and his medical history was significant only Figure 3. Slitlamp photograph of case 3 at postoperative month 1 shows a clear cornea (A), and on for scoliosis and seasonal allergies.
    [Show full text]
  • A Case of Type I Sialidosis with Osteonecrosis Revealing a New
    Original Article Journal of Inborn Errors of Metabolism &Screening 1–3 A Case of Type I Sialidosis With ª The Author(s) 2014 Reprints and permission: Osteonecrosis Revealing a New sagepub.com/journalsPermissions.nav DOI: 10.1177/2326409814543468 Mutation in NEU1 iem.sagepub.com Geoffrey Urbanski1,2, Soumeya Bekri3, Magalie Barth2,4, Christophe Verny4, and Christian Lavigne1,2 Abstract Sialidosis is a rare lysosomal storage disease. The 2 forms described are as follows: the early-onset form, or type II, presents with dysostosis multiplex, while the late-onset form, or type I, does not involve bone in the literature. We report the case of a 42-year- old woman with type I sialidosis who presents with osteonecrosis of both humeral and femoral heads. Molecular study reveals a never listed mutation of NEU1 in exon 5, p.Gly273Asp (c.818G>A), and a second known missense mutation. Keywords sialidosis, bone involvement, NEU1 Introduction developed, at the age of 18 years, a rapidly progressive severe bilateral visual defect leading to blindness. At that time, the Sialidosis (Online Mendelian Inheritance in Man [OMIM] ophthalmologic examination revealed bilateral cherry red spot 256550) is a rare lysosomal storage disease,1 with an estimated in the macula, evolving to macular and optic atrophy associated incidence of 1 in 4 200 000 live births, and it belongs to the group with bilateral cataract. At the age of 32 years, she developed of oligosaccharidoses. Sialidosis is caused by to the recessively myoclonus and epilepsy as grand mal seizure. Myoclonus inherited deficiency of N-acetyl-a-neuraminidase, an acid affected all 4 limbs, but prevailed in the upper limbs, and hydrolase expressed from the gene NEU1, which is located in increased with menstrual cycle and anxiety.
    [Show full text]
  • The Lysosomal Sialic Acid Transporter Sialin Is Required for Normal CNS Myelination
    The Journal of Neuroscience, December 9, 2009 • 29(49):15355–15365 • 15355 Neurobiology of Disease The Lysosomal Sialic Acid Transporter Sialin Is Required for Normal CNS Myelination Laura M. Prolo,1 Hannes Vogel,2 and Richard J. Reimer1 1Department of Neurology and Neurological Sciences and Graduate Program in Neuroscience and 2Departments of Pathology and Pediatrics, Stanford University School of Medicine, Stanford, California 94305 Salla disease and infantile sialic acid storage disease are autosomal recessive lysosomal storage disorders caused by mutations in the gene encoding sialin, a membrane protein that transports free sialic acid out of the lysosome after it is cleaved from sialoglycoconjugates undergoing degradation. Accumulation of sialic acid in lysosomes defines these disorders, and the clinical phenotype is characterized by neurodevelopmental defects, including severe CNS hypomyelination. In this study, we used a sialin-deficient mouse to address how loss of sialin leads to the defect in myelination. Behavioral analysis of the sialin ؊/؊ mouse demonstrates poor coordination, seizures, and premature death. Analysis by histology, electron microscopy, and Western blotting reveals a decrease in myelination of the CNS but normal neuronal cytoarchitecture and normal myelination of the PNS. To investigate potential mechanisms underlying CNS hypomyeli- nation, we studied myelination and oligodendrocyte development in optic nerves. We found reduced numbers of myelinated axons in optic nerves from sialin ؊/؊ mice, but the myelin that was present appeared grossly normal. Migration and density of oligodendrocyte precursorcellswerenormal;however,amarkeddecreaseinthenumberofpostmitoticoligodendrocytesandanassociatedincreaseinthe number of apoptotic cells during the later stages of myelinogenesis were observed. These findings suggest that a defect in maturation of cells in the oligodendrocyte lineage leads to increased apoptosis and underlies the myelination defect associated with sialin loss.
    [Show full text]
  • Cherry-Red Spot Myoclonus Syndrome and A-Neuraminidase Deficiency
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.43.10.934 on 1 October 1980. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry, 1980, 43, 934-940 Cherry-red spot myoclonus syndrome and a-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult S FRANCESCHETTf, G UZIEL, S DI DONATO, L CAIM[*, AND G AVANZfNI From the Departments of Neurophysiology and Neurometabolic Diseases Istituto Neurologico C Besta, Milan, Italy SUMMARY A 22 year old patient with non-familial progressive myoclonus, macular cherry-red spot, moderate cerebellar syndrome and normal intelligence is described. The mycolonus began at the age of 18 years. Focal myoclonus could easily be elicited by voluntary and passive movements, and by touch and electrical stimulation of median nerve. Somatosensory evoked potentials showed a high voltage early component. Jerk-locked averaging of the EEG preceding action myoclonus detected an otherwise hidden, time-related, EEG spike. The myoclonus responded partially but clearly to L-5 hydroxytryptophan plus carbidopa treatment. Biochemical study showed an a-neuraminidase deficiency in cultured fibroblasts: the decrease in this enzyme activity was compared to that found in a patient affected by mucolipidosis III. Protected by copyright. A slowly progressing neurological syndrome that Case report combines action sensitive and stimulus-sensitive myoclonus with cherry-red spots at the macula The patient was an Italian male aged 21 years. in patients with a-neuraminidase deficiency has There was nothing significant in the family history. In The patient was cyanotic at birth but his psycho- been described recently.'-3 these patients, there motor development 'had been normal.
    [Show full text]
  • The Myriad Foresight® Carrier Screen
    The Myriad Foresight® Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.myriadwomenshealth.com | [email protected] | (888) 268-6795 The Myriad Foresight® Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia ...............................................................................................................................................................................8 6-pyruvoyl-tetrahydropterin Synthase Deficiency....................................................................................................................................................................................................10 ABCC8-related Familial Hyperinsulinism..................................................................................................................................................................................................................12 Adenosine Deaminase Deficiency ............................................................................................................................................................................................................................14 Alpha Thalassemia ....................................................................................................................................................................................................................................................16 Alpha-mannosidosis ..................................................................................................................................................................................................................................................18
    [Show full text]